Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GANX | PRESS-RELEASE | mixed | 6/10 | Gain Therapeutics reported financial results for 2025, showing a slight reduction in net loss to $20.2M from $20.4M in 2 | Mar 26, 2026 |
| ABOS | PRESS-RELEASE | mixed | 6/10 | Acumen Pharmaceuticals reported its 2025 financial results, showing increased R&D spending and a wider net loss, while m | Mar 26, 2026 |
| MPLT | PRESS-RELEASE | neutral | 5/10 | MapLight Therapeutics reported financial results for Q4 and full year 2025, highlighting a significant increase in R&D a | Mar 26, 2026 |
| HYPD | PRESS-RELEASE | mixed | 6/10 | Hyperion DeFi reported Q4 2025 results showing strong growth in Adjusted Gross Profit, which rose 87% quarter-over-quart | Mar 26, 2026 |
| LFCR | PRESS-RELEASE | bullish | 7/10 | Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer: on | Mar 26, 2026 |
| AGMB | PRESS-RELEASE | neutral | 5/10 | AgomAb Therapeutics announced the issuance of a U.S. patent (No. 12,577,230) covering the composition of matter for its | Mar 26, 2026 |
| TNXP | PRESS-RELEASE | neutral | 5/10 | Tonix Pharmaceuticals announced the first participant dosed in a Phase 1 investigator-initiated study evaluating TNX-190 | Mar 26, 2026 |
| KMDA | PRESS-RELEASE | bullish | 7/10 | Kamada Ltd. announced FDA approval for its San Antonio plasma collection center, enabling commercial sales of normal sou | Mar 26, 2026 |
| AAPG | PRESS-RELEASE | mixed | 6/10 | Ascentage Pharma reported unaudited 2025 financial results showing a 41.5% year-over-year decline in total revenue to $8 | Mar 25, 2026 |
| OGEN | PRESS-RELEASE | bearish | 7/10 | Oragenics issued a press release to comply with NYSE American rules, confirming that its audited financial statements fo | Mar 25, 2026 |
| XRTX | PRESS-RELEASE | neutral | 5/10 | XORTX Therapeutics is consolidating its shares on a 1:5 basis to maintain compliance with Nasdaq's $1.00 minimum bid pri | Mar 25, 2026 |
| DYAI | PRESS-RELEASE | mixed | 5/10 | Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.09 million from $3.50 | Mar 25, 2026 |
| BYSI | PRESS-RELEASE | neutral | 3/10 | BeyondSpring filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, which includes audited fi | Mar 25, 2026 |
| SER | PRESS-RELEASE | mixed | 7/10 | Serina Therapeutics announced FDA clearance of its IND for SER-252, a POZ-apomorphine therapy for advanced Parkinson's d | Mar 25, 2026 |
| XCUR | PRESS-RELEASE | bearish | 8/10 | Exicure reported its 2025 financial results, showing a reduced net loss of $4.9 million compared to $9.7 million in 2024 | Mar 25, 2026 |
| EBS | PRESS-RELEASE | bullish | 7/10 | Emergent BioSolutions announced a $54 million contract extension with the U.S. government for VIGIV, a treatment for sma | Mar 25, 2026 |
| REGN | PRESS-RELEASE | neutral | 2/10 | Regeneron Pharmaceuticals announced it will release its first quarter 2026 financial results on April 29, 2026, followed | Mar 25, 2026 |
| OTLK | PRESS-RELEASE | neutral | 5/10 | Outlook Therapeutics (OTLK) closed a public offering of 20 million shares and accompanying warrants to purchase 20 milli | Mar 25, 2026 |
| EQ | PRESS-RELEASE | bearish | 6/10 | Equillium reported $0 revenue for Q4 and full-year 2025, a sharp decline from $4.4M and $41.1M in the prior year due to | Mar 25, 2026 |
| NERV | PRESS-RELEASE | neutral | 5/10 | Minerva Neurosciences announced positive safety data from an open-label trial showing no clinically significant adverse | Mar 25, 2026 |
| NKTX | PRESS-RELEASE | neutral | 5/10 | Nkarta reported financial results for Q4 and full year 2025, highlighting a cash balance of $295.1 million, which is exp | Mar 25, 2026 |
| DERM | PRESS-RELEASE | bullish | 7/10 | Journey Medical Corporation reported FY2025 revenue of $61.9 million, a 10% increase from $56.1 million in FY2024, drive | Mar 25, 2026 |
| TVGN | PRESS-RELEASE | neutral | 4/10 | Tevogen Bio (TVGN) announced it has regained compliance with Nasdaq's $1.00 minimum bid price requirement, resolving a d | Mar 25, 2026 |
| ONCO | PRESS-RELEASE | bullish | 7/10 | Onconetix, Inc. (ONCO) announced that Realbotix, the target of its pending all-stock acquisition, had a humanoid robot f | Mar 25, 2026 |
| DNLI | PRESS-RELEASE | bullish | 9/10 | Denali Therapeutics announced FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the first biologic therapy | Mar 25, 2026 |
| GHRS | PRESS-RELEASE | bullish | 8/10 | GH Research PLC announced the publication of Phase 2b trial results for its lead candidate GH001 in treatment-resistant | Mar 25, 2026 |
| NBTX | PRESS-RELEASE | neutral | 3/10 | Nanobiotix (NBTX) issued a press release denying recent media speculation about a potential takeover, stating that no ac | Mar 25, 2026 |
| NSRX | PRESS-RELEASE | mixed | 6/10 | Nasus Pharma released its 2025 annual results and provided a business update, highlighting positive Phase 2 data for its | Mar 25, 2026 |
| BYSI | PRESS-RELEASE | bullish | 8/10 | BeyondSpring reported its 2025 financial results and highlighted significant clinical progress for its lead asset, Plina | Mar 25, 2026 |
| IXHL | PRESS-RELEASE | neutral | 3/10 | Incannex Healthcare announced a partnership with the AASM Foundation to sponsor a grant for junior researchers focused o | Mar 25, 2026 |